Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR^2 (Trametinib, Retifanlimab, and Ruxolitinib) in Metastatic Pancreatic Ductal Adenocarcinoma
NCT05440942Phase 1Completed
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of trametinib, ruxolitinib and retifanlimab in pancreatic ductal adenocarcinoma (PDAC) (3 arms). Primary endpoint: Recommended Phase 2 Dose at 6 months. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05440942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440942.